Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing

Outcome of immune checkpoint inhibition in cancer can be predicted by measuring PDL1 expression of tumor cells. Search for additional biomarkers led to tumor mutational burden (TMB) as surrogate marker for neoantigens presented. While TMB was previously determined via whole exome sequencing (WES), t...

Descripción completa

Detalles Bibliográficos
Autores principales: Heydt, Carina, Rehker, Jan, Pappesch, Roberto, Buhl, Theresa, Ball, Markus, Siebolts, Udo, Haak, Anja, Lohneis, Philipp, Büttner, Reinhard, Hillmer, Axel M., Merkelbach-Bruse, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347536/
https://www.ncbi.nlm.nih.gov/pubmed/32647293
http://dx.doi.org/10.1038/s41598-020-68394-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347536/
https://www.ncbi.nlm.nih.gov/pubmed/32647293
http://dx.doi.org/10.1038/s41598-020-68394-4

Ejemplares similares